Who are FUROSEMIDE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TORSEMIDE, Bumex, Edecrin, Lasix, nesiritide, furosemide, placebo+torasemide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chembl-chembl35.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

FUROSEMIDE — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FUROSEMIDE (FUROSEMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Loop Diuretic [EPC].

marketed Loop Diuretic [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

FUROSEMIDE (FUROSEMIDE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
FUROSEMIDE TARGET	FUROSEMIDE		marketed	Loop Diuretic [EPC]		1966-01-01
TORSEMIDE	TORSEMIDE		marketed	Loop Diuretic [EPC]	Na+/K+/2Cl- carrier system	1993-01-01
Bumex	BUMETANIDE		marketed	Loop Diuretic [EPC]	Solute carrier family 12 member 1	1983-01-01
Edecrin	ETHACRYNIC ACID	Bausch Health	marketed	Loop Diuretic [EPC]	Glutathione S-transferase P	1967-01-01
Lasix	furosemide	Generic (originally Hoechst AG)	marketed	Loop Diuretic [EPC]	ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35	1966-07-01
nesiritide, furosemide	nesiritide, furosemide	Scios, Inc.	marketed	Natriuretic peptide analog and loop diuretic combination	Natriuretic peptide receptor-A (NPR-A) and Na-K-2Cl cotransporter
placebo+torasemide	placebo+torasemide	Shanghai Chest Hospital	marketed	Loop diuretic	Na-K-2Cl cotransporter (NKCC2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-10-06 — TORSEMIDE · 10154963 · Formulation · US
2034-04-03 — Lasix · 9884039 · Method of Use · US
2034-04-03 — Lasix · 11433044 · Method of Use · US
2034-04-03 — Lasix · 12370168 · Formulation · US
2034-04-03 — Lasix · 10272064 · Formulation · US
2040-12-04 — Bumex · 11123319 · Formulation · US
2040-12-04 — Bumex · 11260038 · Method of Use · US
2040-12-04 — Bumex · 12329731 · Formulation · US

Sponsor landscape (Loop Diuretic [EPC] class)

· 3 drugs in this class
Bausch Health · 1 drug in this class
Generic (originally Hoechst AG) · 1 drug in this class
Johannes Grand · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FUROSEMIDE — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl35. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing